CTLA4 and melanoma: In the phase III CheckMate 067 trial (NCT01844505) in advance melanoma, durable clinical benefit was demonstrated with nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA4) combination over monotherapy with nivolumab or ipilimumab (111).